Evidence map›Paper›PMID 33684179›Full record

ArticlePLoS pathogens2021

Type I IFNs facilitate innate immune control of the opportunistic bacteria Burkholderia cenocepacia in the macrophage cytosol.

Michael G Dorrington, Clinton J Bradfield, Justin B Lack, Bin Lin, Jonathan J Liang, Tregei Starr, Orna Ernst, Julia L Gross, Jing Sun, Alexandra H Miller and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Opsonization Improves Dual Proteomic Analysis ofJournal of proteome research · 2026
    Article
  2. Review
  3. A type VI secretion system inInfection and immunity · 2024
    Article
  4. Article
  5. Article
  6. Frontiers in cellular and infection microbiology · 2024
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Michael G DorringtonSignaling Systems Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, Maryland, United States of America.ORCID 0000-0002-2083-1229
Clinton J BradfieldSignaling Systems Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, Maryland, United States of America.
Justin B LackNIAID Collaborative Bioinformatics Resource, Frederick National Laboratory for Cancer Research, NIH, Frederick, Maryland, United States of America.
Bin LinSignaling Systems Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, Maryland, United States of America.ORCID 0000-0002-8032-937X
Jonathan J LiangSignaling Systems Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, Maryland, United States of America.
Tregei StarrSalmonella-Host Cell Interactions Section, Laboratory of Bacteriology, NIAID, NIH, Hamilton, Montana, United States of America.ORCID 0000-0003-1561-8834
Orna ErnstSignaling Systems Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, Maryland, United States of America.ORCID 0000-0002-8879-249X
Julia L GrossSignaling Systems Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, Maryland, United States of America.ORCID 0000-0002-3744-7258
Jing SunSignaling Systems Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, Maryland, United States of America.ORCID 0000-0002-4315-7919
Alexandra H MillerSignaling Systems Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, Maryland, United States of America.ORCID 0000-0001-8104-0554
Olivia Steele-MortimerSalmonella-Host Cell Interactions Section, Laboratory of Bacteriology, NIAID, NIH, Hamilton, Montana, United States of America.ORCID 0000-0002-3744-4217
Iain D C FraserSignaling Systems Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, Maryland, United States of America.ORCID 0000-0003-2272-3907
National Institutes of Health · USFrederick National Laboratory for Cancer Research · US

Funding

The Salmonella-Containing VacuoleZIAAI000909 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI STEELE-MORTIMER, OLIVIA · 2009 to 2025
$12.9M
RNAi Screening in Hematopoietic CellsZIAAI001106 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FRASER, IAIN · 2009 to 2025
$12.4M
Analysis of Innate Immune Signaling NetworksZIAAI001107 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FRASER, IAIN · 2009 to 2025
$11.9M
6 · The paper itself

Abstract

The mammalian immune system is constantly challenged by signals from both pathogenic and non-pathogenic microbes. Many of these non-pathogenic microbes have pathogenic potential if the immune system is compromised. The importance of type I interferons (IFNs) in orchestrating innate immune responses to pathogenic microbes has become clear in recent years. However, the control of opportunistic pathogens-and especially intracellular bacteria-by type I IFNs remains less appreciated. In this study, we use the opportunistic, Gram-negative bacterial pathogen Burkholderia cenocepacia (Bc) to show that type I IFNs are capable of limiting bacterial replication in macrophages, preventing illness in immunocompetent mice. Sustained type I IFN signaling through cytosolic receptors allows for increased expression of autophagy and linear ubiquitination mediators, which slows bacterial replication. Transcriptomic analyses and in vivo studies also show that LPS stimulation does not replicate the conditions of intracellular Gram-negative bacterial infection as it pertains to type I IFN stimulation or signaling. This study highlights the importance of type I IFNs in protection against opportunistic pathogens through innate immunity, without the need for damaging inflammatory responses.

Indexed as

AnimalsBurkholderia cenocepaciaBurkholderia InfectionsCytosolFemaleImmunity, InnateInterferon Type IMacrophagesMaleMiceMice, Inbred C57BLInterferon Type I

Identifiers

PMID33684179
PMCPMC7971856
OpenAlexW3134522874

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.